2250228-51-2
Chemical Structure
DYRKtide
- CAS No.: 2250228-51-2
- Formula:C79H135N31O17
- Molecular Weight:1791.11
InChIKey: MHTXZHOYPJLNHB-VOCFVMJUSA-N
SMILES: O=C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CCCNC(N)=N)C(N2[C@@H](CCC2)C(N[C@@H](C)C(N[C@@H](CO)C(N3[C@@H](CCC3)C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(NCC(N4[C@@H](CCC4)C(N5[C@@H](CCC5)C(N[C@@H](CCCCN)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CCCNC(N)=N)N
Biological Activity: DYRKtide is a peptide substrate for DYRK family kinases and can be used to measure DYRK1A substrate phosphorylation and the catalytic activity of DYRK1A mutants. DYRKtide can be used in studies related to in vitro kinase activity assays and in research on DYRK1A-related diseases[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
DYRKtide | 99.57% | DYRKtide is a peptide substrate for DYRK family kinases and can be used to measure DYRK1A substrate phosphorylation and the catalytic activity of DYRK1A mutants. DYRKtide can be used in studies related to in vitro kinase activity assays and in research on DYRK1A-related diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.75
HY-105067ATertomotide hydrochloride -
Similarity Score 0.75
HY-P1595CREBtide -
Similarity Score 0.75
HY-P10280ATR kinase substrate peptide -
Similarity Score 0.74
HY-P10021Tapderimotide -
Similarity Score 0.74
HY-P2243D-JBD19 -
Similarity Score 0.74
HY-P11299EBNA-1 (386–405 aa) -
Similarity Score 0.73
HY-P11396Metalnikowin I -
Similarity Score 0.73
HY-P5440ERKtide -
Similarity Score 0.73
HY-P3886Substance P-Gly-Lys-Arg -
Explore the MedChemAI to find more analogs
References
- [1]. Kii I, et al. Selective inhibition of the kinase DYRK1A by targeting its folding process. Nature communications. 2016 Apr 22;7:11391.
- [2]. Göckler N, et al. Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation. The FEBS journal. 2009 Nov;276(21):6324-37.
- [3]. Yuan K, et al. Targeting dual-specificity tyrosine phosphorylation-regulated kinase 2 with a highly selective inhibitor for the treatment of prostate cancer. Nature communications. 2022 May 25;13(1):2903. [Content Brief]
- [4]. Arranz J, et al. Impaired development of neocortical circuits contributes to the neurological alterations in DYRK1A haploinsufficiency syndrome. Neurobiology of disease. 2019 Jul;127:210-222.
- [5]. Barzowska A, et al. DYRK1A Kinase Inhibitors Promote β-Cell Survival and Insulin Homeostasis. Cells. 2021 Aug 31;10(9):2263.
